Literature DB >> 6751739

Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy.

A Pietri, P Raskin.   

Abstract

The cutaneous complications that can develop with continuous subcutaneous insulin infusion constitutes a significant concern when using this innovative and highly effective form of treatment for type I diabetes. These complications are twofold, the first being infection with abscess formation at the infusion needle site. Proper hygiene and frequent changing of the infusion site are helpful and effective measures. The second complication is the development of local allergic skin reactions, again at the infusion needle site, even with highly purified pork insulin. These may subside after several weeks on their own but switching insulin preparations also may be helpful.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6751739     DOI: 10.2337/diacare.4.6.624

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Insulin allergy.

Authors:  L Grammer
Journal:  Clin Rev Allergy       Date:  1986-05

Review 3.  Insulin treatment: a non-stop revolution.

Authors:  J Mirouze
Journal:  Diabetologia       Date:  1983-09       Impact factor: 10.122

4.  Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome.

Authors:  C S Filgueira; E Nicolov; R L Hood; A Ballerini; J Garcia-Huidobro; J Z Lin; D Fraga; P Webb; O M Sabek; A O Gaber; K J Phillips; A Grattoni
Journal:  Int J Obes (Lond)       Date:  2016-07-27       Impact factor: 5.095

5.  Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.

Authors:  Tina K Thethi; Ajay Rao; Haytham Kawji; Tilak Mallik; C Lillian Yau; Uwe Christians; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2009-04-23       Impact factor: 2.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.